Modulation of innate immune signalling pathways by viral proteins

Advances in Experimental Medicine and Biology

Volumn 666, Issue , 2009, Pages 49-63

  Mulhern, Orla ^b   Harrington, Barry ^b   Bowie, Andrew G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAS ASSOCIATED DEATH DOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON BETA PROMOTER STIMULATOR 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 10; MYELOID DIFFERENTIATION FACTOR 88; MYELOID DIFFERENTIATION FACTOR 88 ADAPTOR LIKE; PROTEIN KINASE R; RETINOIC ACID INDUCIBLE PROTEIN I; RETINOIC ACID INDUCIBLE PROTEIN I LIKE HELICASE; TIR DOMAIN CONTAINING ADAPTOR INDUCING INTERFERON BETA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; Z DNA BINDING PROTEIN;

ADENOVIRUS; ARTICLE; CELL SURVIVAL; CPG ISLAND; CYTOKINE PRODUCTION; DNA BINDING; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; INNATE IMMUNITY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; VACCINIA VIRUS; VIRUS ACTIVATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; HUMAN; PATHOGENICITY; PHYSIOLOGY; REVIEW; VIROLOGY; VIRUS;

HUMANS; IMMUNITY, INNATE; SIGNAL TRANSDUCTION; VIRAL PROTEINS; VIRUS DISEASES; VIRUSES;

EID: 75649132240     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1601-3_4     Document Type: Article

References (100)

1. Garcia MA, Meurs EF, Esteban M. The dsRNA protein kinase PKR: Virus and cell control. Biochimie 2007; 89(6-7):799-811. (Pubitemid 47001637)
2. Metz DH, Esteban M. Interferon inhibits viral protein synthesis in L-cells infected with vaccinia virus. Nature 1972; 238(5364):385-388.
3. Karze MG, DeCorato D, Safer B et al. Adenovirus VAI RNA complexes with the 68,000 Mr protein kinase to regulate its autophosphorylation and activity. EMBO J 1987; 6(3):689-697.
4. Maitra RK, McMillan NA, Desai S et al. HIV-1 TAR RNA has an intrinsic ability to activate interferon-inducible enzymes. Virology 1994; 204(2):823-827. (Pubitemid 24330891)
5. Ito T, Yang M, May WS. RAX, a cellular activaror for double-stranded RNA-dependent protein kinase during stress signaling. J Biol Chem 1999; 274(22):15427-15432.
6. Patel RC, Sen GC. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J 1998; 17(15):4379-4390. (Pubitemid 28362628)
7. Nallagatla SR, Hwang J, Toroney R et al. 5'-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science 2007; 318(5855):1455-1458. (Pubitemid 350208957)
8. Garcia MA, Gil J, Ventoso I et al. Impact of protein kinase PKR in cell biology: From antiviral to antiproliferative action. Microbiol Mol Biol Rev 2006; 70(4):1032-1060. (Pubitemid 44958263)
9. Williams BR. Signal integration via PKR. Sci STKE 2001; 2001(89):RE2.
10. Verma IM, Stevenson JK, Schwarz EM et al. Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation. Genes Dev 1995; 9(22):2723-2735. (Pubitemid 3009952)
11. Jiang Z, Zamanian-Daryoush M, Nie H et al. Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAKI-TAB2-PKR. J Biol Chem 2003; 278(19):16713-16719. (Pubitemid 36799536)
12. Clemens MJ. PKR-A protein kinase regulated by double-stranded RNA. Inr J Biochem Cell Bioi 1997; 29(7):945-949. (Pubitemid 27478880)
13. Beatrie E, Paoletti E, Tartaglia J. Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses. Virology 1995; 210(2):254-263.
14. Langland JO, Pettiford S, Jiang B et al. Products of the porcine group C roravirus NSP3 gene bind specifically to double-stranded RNA and inhibit activation of the interferon-induced protein kinase PKR. J Viro11994; 68(6):3821-3829. (Pubitemid 24177407)
15. Shors T, Kibler KY, Perkins KB et al. Complementation of vaccinia virus deleted of the E3L gene by mutants of E 31 Virology 1997; 239(2):269-276. (Pubitemid 28105633)
16. Langland JO, Cameron JM. Heck MC et al. Inhibition of PKR by RNA and DNA viruses. Virus Res 2006; 119(1):100-110. (Pubitemid 43765973)
17. Lu Y, Wambach M, Katze MG et al. Binding of the influenza virus NSl protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor. Virology 1995; 214(1):222-228.
18. Wang W, Riedel K, Lynch P et al. RNA binding by the novel helical domain of the influenza virus NSl protein requires its dimer structure and a small number of specific basic amino acids. RNA 1999; 5(2):195-205. (Pubitemid 29079280)
19. Khoo D, Perez C, Mohr 1 Characterization of RNA determinants recognized by the arginine- and proline-rich region of UsU, a herpes simplex virus Type l-encoded double-stranded RNA binding protein that prevents PKR activation. J Viro12002; 76(23):11971-11981. (Pubitemid 35304297)
20. Poppers J, Mulvey M, Perez C et al. Identification of a lytic-cycleEpsrein-Barr virus gene product that can regulate PKR activation. J Viro12003; 77(1):228-236. (Pubitemid 36004963)
21. VyasJ, Elia A, Clemens MJ. Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA. RNA 2003; 9(7):858-870. (Pubitemid 36734783)
22. Clarke PA, Schwemmle M, Schickinger Jet al. Binding of Epstein-Barr virus small RNA EBER-l to the double-stranded RNA-activated protein kinase DAL Nucleic Acids Res 1991; 19(2):243-248. (Pubitemid 21896965)
23. Sharp TV; SchwemmleM, Jefttey I et al. Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epsrein-Barrvirus RNAs EBER-l and EBER-2 and adenovirusVAI RNA. Nucleic Acids Res 1993; 21(19):4483-4490. (Pubitemid 23292710)
24. Clarke PA, Sharp NA, Clemens MJ. Translational control by the Epstein-Barr virus small RNA EBER-1. Reversal of the double-stranded RNA-induced inhibition of protein synthesis in reticulocyte lysares. Eur J Biochem 1990; 193(3):635-641. (Pubitemid 20381692)
25. Gale MJ Jr, Korth MJ, Tang NM et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstrucrural 5A protein. Virology 1997; 230(2):217-227. (Pubitemid 27211852)
26. Tan SL, Gale MJ Jr, Katze MG. Double-stranded RNA-independent dimerization of interferon-induced protein kinase PKR and inhibition of dimerization by the cellular P581PK inhibitor. Mol Cell Biol 1998; 18(5):2431-2443. (Pubitemid 28183413)
27. Taylor DR, Shi ST, Romano PR et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285(5424):107-110. (Pubitemid 29307576)
28. Pavio N, Taylor DR, Lai MM. Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. J Viro12002; 76(3):1265-1272. (Pubitemid 34066430)
29. Lee TG, Tomita J, Hovanessian AG et al. Characterization and regulation of the 58,000-dalton cellular inhibitor of the interferon-induced, dsRNA-activated protein kinase. J BioI Chem 1992; 267(20): 14238-14243.
30. Romano PR, Zhang F,Tan SL et al. Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 Nvterminal domain. Mol Cell Bioi 1998; 18(12):7304-7316. (Pubitemid 28533050)
31. Black TL, Barber GN, Katze MG. Degradation of the interferon-induced 68,000-M(r) protein kinase by poliovirus requires RNA. J Viro11993; 67(2):791-800. (Pubitemid 23032057)
32. Chou J, Chen JJ, Gross M et al. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1 Proc Narl Acad Sci USA 1995; 92(23):10516-10520. (Pubitemid 3009119)
33. Kazemi S, Papadopoulou S, Li S et al. Control of alpha subunit of eukaryoric translation initiation factor 2 (eIF2 a) phosphorylation by the human papillomavirus Type 18 E6 oncoprotein: Implications for eIF2 alpha-dependent gene expression and cell death. Mol Cell BioI 2004; 24(8):3415-3429. (Pubitemid 38452084)
34. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988; 52(2):269-279.
35. Lemaitre B, Nicolas E, Michaut L et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in drosophila adults. Cell 1996; 86(6):973-983. (Pubitemid 26336801)
36. Zambon RA, Nandakumar M, VakhariaVN et al. The Toll pathway is important for an antiviral response in drosophila. Proc Natl Acad Sci USA 2005; 102(20):7257-7262. (Pubitemid 40696366)
37. Yang LFR YL, Pavlovic J, Aguzzi A et al. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J 1995; 14(24):6095-6106.
38. Zhou A, Paranjape JM, Der SD et al. Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology 1999; 258(2):435-440. (Pubitemid 29390253)
39. Lena Alexopoulou ACH, Ruslan Medzhitov, Richard Flavell A. Recognition of double-stranded RNA and activation of NF-B by Toll-like receptor 3 Nature 2001; 413:732-738. (Pubitemid 33009951)
40. Schroder M, Bowie AG. TLR3 in antiviral immunity: Key player or bystander? Trends in Immunology 2005; 26(9):462-468. (Pubitemid 41139255)
41. Marsumoto M, Funami K, Tanabe M et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003; 171(6):3154-3162. (Pubitemid 37093540)
42. Weber F, Wagner V; Rasmussen SB et al. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol 2006; 80(10):5059-5064.
43. Schulz O, Diebold SS, Chen M et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005; 433(7028):887-892. (Pubitemid 40314900)
44. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408(6813):740-745. (Pubitemid 32015992)
45. Krug A, Luker GD, Barchet W et al. Herpes simplex virus Type 1 activates murine natural interferon- producing cells through toll-like receptor 9 Blood 2004; 103(4):1433-1437. (Pubitemid 38168659)
46. Lund J, Saro A, Akira S et al. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003; 198(3):513-520. (Pubitemid 36976063)
47. Latz E, Schoenemeyer A, Visintin A et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nar Immunol 2004; 5(2):190-198. (Pubitemid 38208361)
48. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 Science 2004; 303(5663):1526-1529. (Pubitemid 38314424)
49. Lund JM, Alexopoulou L, Sato A et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004; 101(15):5598-5603. (Pubitemid 38481202)
50. Diebold SS, Massacrier C, Akira S et al. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J Immuno12006; 36(12):3256-3267. (Pubitemid 44932727)
51. Kurt-jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1(5):398-401.
52. Ehl S, Bischoff R, Ostler T et al. The role of Toll-like receptor 4 versus interleukin-12 in immunity to respiratory syncytial virus. Eur J Immunol 2004, 34(4):1146-1153. (Pubitemid 39255994)
53. Kurt-jones EA, Chan M, Zhou S et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci USA 2004; 101(5):1315-1320. (Pubitemid 38182686)
54. Zhu J, Martinez J, Huang X et al. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 2007; 109(2):619-625. (Pubitemid 46105962)
55. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007, 7(5):353-364. (Pubitemid 46674493)
56. Carry M, Goodbody R, Schroder M et al. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol2006; 7(10):1074-1081. (Pubitemid 44420652)
57. Keating SE, Maloney GM, Moran EM et al. IRAK-2 participates in multiple toll-like receptor signaling pathways to NFkappaB via activation of TRAF6 ubiquitination. J Bioi Chem 2007; 282(46):33435-33443. (Pubitemid 350159553)
58. Bowie A, Kiss-Toth E, Symons JA et al. A46R and A52R from vaccinia virus are antagonists of host IL-l and toll-like receptor signaling. Proc Natl Acad Sci USA 2000; 97(18):10162-10167.
59. Harte MT, Haga IR, Maloney G et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 2003, 197(3):343-351. (Pubitemid 36184241)
60. Maloney G, Schroder M, Bowie AG. Vaccinia virus protein A52R activates p38 mitogen-activated protein kinase and potenriares lipopolysaccharide-induced interleukin-l O, J Bioi Chem 2005; 280(35):30838-30844. (Pubitemid 41291814)
61. Meylan E, Burns K, Hofmann K et al. RIPl is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immuno12004; 5(5):503-507. (Pubitemid 38660462)
62. Cusson-Herrnance N, Khurana S, Lee TH et al. Ripl mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. J Bioi Chem 2005; 280(44):36560-36566. (Pubitemid 41587731)
63. Kim TW; Staschke K, BulekK et al.A critical role for IRAK4 kinase activity in Toll-likereceptor-mediared innate immunity. J Exp Med 2007; 204(5):1025-1036. (Pubitemid 46798147)
64. Uematsu S, Sato S, Yamamoto M et al. Interleukin-I receptor-associated kinase-I plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J Exp Med 2005, 201(6):915-923. (Pubitemid 40524461)
65. Hoshino K, Sugiyama T, Matsumoto M et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9 Nature 2006; 440(7086) :949-953.
66. Stack J, Haga IR, Schroder M et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-I receptor adaptors and contributes to virulence. J Exp Med 2005; 201(6):1007-1018. (Pubitemid 40524469)
67. Cirl C, Wieser A, YadavM et al. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/Interleukin-I receptor domain-containing proteins. Nat Med 2008; 14(4):399-406. (Pubitemid 351499388)
68. Li K, Foy E, Ferreon JC et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005; 102(8):2992-2997. (Pubitemid 40299904)
69. Wang T, Town T, Alexopoulou L et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004; 10(12):1366-1373. (Pubitemid 40022719)
70. Hutchens M, Luker KE, Sottile P et al. TLR3 increases disease morbidity and mortality from vaccinia infection. J Immunol2008; 180(1):483-491.
71. Moore Kw; de Waal Malefyt R, Coffman RL et al. Interleukin-l0 and the interleukin-1O receptor. Annu Rev Immuno12001; 19:683-765.
72. Brooks DG, Trifilo MJ, Edelmann KH et al. Interleukin-1O determines viral clearance or persistence in vivo. Nat Med 2006; 12(11):1301-1309. (Pubitemid 44706933)
73. Ejrnaes M, Filippi CM, Martinic MM et al. Resolution of a chronic viral infection after interleukin-l0 receptor blockade. J Exp Med 2006; 203(11):2461-2472. (Pubitemid 44664616)
74. Jude BA, Pobezinskaya Y, Bishop Jet al. Subversion of the innate immune system by a retrovirus. Nat Immunol 2003; 4(6):573-578. (Pubitemid 36701341)
75. Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol2004; 5(7):730-737. (Pubitemid 39023305)
76. AndrejevaJ, Childs KS, Young DF et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5 and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci USA 2004; 101(49):17264-17269. (Pubitemid 39627808)
77. Saito T, Hirai R, Loo YM et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP 2 Proc Natl Acad Sci USA 2007; 104(2):582-587. (Pubitemid 46123068)
78. Rothenfusser S, Goutagny N, DiPerna G et al. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol 2005; 175(8):5260-5268. (Pubitemid 41456411)
79. Komuro A, Horvath CM. RNA- and virus-independent inhibition of antiviral signaling by RNA helicase LGP2.J Virol 2006; 80(24):12332-12342. (Pubitemid 44904383)
80. Kato H, Takeuchi O, Sato S et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441(7089):101-105.
81. Takeuchi O, Akira S. Recognition of viruses by innate immunity. Immunol Rev 2007; 220:214-224. (Pubitemid 350045565)
82. Pichlmair A, Schulz O, Tan CP et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006; 314(5801):997-1001. (Pubitemid 44749946)
83. Hornung V, Ellegasr J, Kim S et al 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006; 314(5801 ):994-997.
84. Kawai T, Takahashi K, Sato S et al. IPS-l, an adaptor triggering RIG-I- and Mda5-mediated Type I interferon induction. Nat Immuno12005; 6(10):981-988. (Pubitemid 41486182)
85. Serh RB, Sun L, Ea CK et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3 Cell 2005; 122(5):669-682. (Pubitemid 41242633)
86. Xu LG, Wang YY, Han KJ et al. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005; 19(6):727-740.
87. Meylan E, CurranJ, Hofmann K et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437(7062):1167-1172. (Pubitemid 41509355)
88. Kumar H, Kawai T, Kato H et al. Essential role of IPS-l in innate immune responses against RNA viruses.J Exp Med 2006; 203(7):1795-1803. (Pubitemid 44036284)
89. Sun Q, Sun L, Liu HH et al. The specific and essential role of MAVS in antiviral innate immune responses. Immunity 2006; 24(5):633-642. (Pubitemid 43728147)
90. Loo YM, Owen DM, Li K et al. Viral and therapeutic control ofIFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 2006; 103(15):6001-6006.
91. Saha SK, Pietras EM, He JQ et al. Regulation of antiviral responses by a direct and specific interaction between TRAB and Cardif. EMBOJ 2006; 25(14):3257-3263. (Pubitemid 44141784)
92. Pichlmair A, Reise Sousa C. Innate recognition of viruses. Immunity 2007; 27(3):370-383. (Pubitemid 47418682)
93. YangY,Liang Y,Qu L et al. Disruption of innate immunity due to mitochondrial targering of a picornaviral protease precursor. Proc Natl Acad Sci USA 2007; 104(17):7253-7258. (Pubitemid 47186041)
94. Takaoka A, Wang Z, Choi MK et al. DAI (DLM-lIZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448(7152):501-505. (Pubitemid 47123520)
95. Kim YG, Muralinath M, Brandt T et al. A role for Z-DNA binding in vaccinia virus pathogenesis. Proc Natl Acad Sci USA 2003; 100(12):6974-6979. (Pubitemid 36706378)
96. Unrerholzner L, BowieAG. The interplay between viruses and innate immune signaling: Recent insighrs and therapeutic opportunities. Biochem Pharmacol 2008; 75(3):589-602.
97. Unrersrab G, Ludwig S, Anton A et al. Viral targeting of the interferon-{beta}-inducing Traf family member-associated NF-{kappa}B activator (TANK)-binding kinase-I. Proc Natl Acad Sci USA 2005; 102(38): 13640-13645. (Pubitemid 41420901)
98. Lin R, Genin P, Mamane Y et al. HHV-8 encoded vlRF-l represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators, Oncogene 2001; 20(7):800-811. (Pubitemid 32198173)
99. Santoro MG, Rossi A, Amici C. NF-kappaB and virus infection: Who controls whom. EMBO J 2003; 22(11):2552-2560. (Pubitemid 36712353)
100. Hiscott J, Nguyen TL, Arguello M et al. Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene 2006; 25(51):6844-6867. (Pubitemid 44657856)